Research Topics
| Steven JoffeSummaryAffiliation: Harvard University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Equipoise: asking the right questions for clinical trial designSteven Joffe
Department of Pediatric Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
Nat Rev Clin Oncol 9:230-5. 2012..An alternate approach to risk-benefit assessment that is congruent with the scientific purpose of RCTs can better guide ethical evaluation of these trials, as discussed in this Perspective...
Involving children with cancer in decision-making about research participationSteven Joffe
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
J Pediatr 149:862-868. 2006
Views of American oncologists about the purposes of clinical trialsSteven Joffe
Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Natl Cancer Inst 94:1847-53. 2002..Many research subjects believe incorrectly that the primary purpose of clinical trials is to benefit the participants rather than to improve therapy for future patients. However, few data are available about how physicians view trials...
What do patients value in their hospital care? An empirical perspective on autonomy centred bioethicsS Joffe
Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Med Ethics 29:103-8. 2003..We sought to examine the relative influence of involvement in decisions, confidence and trust in providers, and treatment with respect and dignity on patients' evaluations of their hospital care...
Public dialogue and the boundaries of moral communitySteven Joffe
Dana-Farber Cancer Institute and Children's Hospital, USA
J Clin Ethics 14:101-8. 2003
Advance care planning in patients undergoing hematopoietic cell transplantationSteven Joffe
Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Biol Blood Marrow Transplant 13:65-73. 2007..Even though ACP was more prevalent among this sample than in the general population, its use still could be enhanced, given the high risks of decisional incapacity and death that HCT patients face...
Satisfaction of the uncertainty principle in cancer clinical trials: retrospective cohort analysisSteven Joffe
Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
BMJ 328:1463. 2004..This principle is violated if trials systematically favour either the experimental or the standard treatment...
Pediatricians' reports of their education in ethicsJennifer Cohn Kesselheim
Department of Pediatric Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Arch Pediatr Adolesc Med 162:368-73. 2008..To study pediatricians' assessments of the quality of their ethics education, the impact of various learning methods, and their confidence in confronting ethical dilemmas arising in pediatric practice...
Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured reviewJeffrey M Peppercorn
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Lancet 363:263-70. 2004..Until such data are available, patients with cancer should be encouraged to enroll in clinical trials on the basis of trials' unquestioned role in improving treatment for future patients...
Considerations about hastening death among parents of children who die of cancerVeronica Dussel
Center for Outcomes and Policy Research and Department of Psychosocial Oncology and Palliative Care, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Arch Pediatr Adolesc Med 164:231-7. 2010....
A randomized study of how physicians interpret research funding disclosuresAaron S Kesselheim
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
N Engl J Med 367:1119-27. 2012..The effects of clinical-trial funding on the interpretation of trial results are poorly understood. We examined how such support affects physicians' reactions to trials with a high, medium, or low level of methodologic rigor...
Rethinking risk-benefit assessment for phase I cancer trialsSteven Joffe
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
J Clin Oncol 24:2987-90. 2006
Private cord blood banking: experiences and views of pediatric hematopoietic cell transplantation physiciansIan Thornley
Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Pediatrics 123:1011-7. 2009..Pediatric hematopoietic cell transplantation physicians are currently best situated to use cord blood therapeutically. We sought to describe the experiences and views of these physicians regarding private cord blood banking...
Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participantsAnn H Partridge
Dana Farber Cancer Institute, Boston, MA 02115, USA
J Natl Cancer Inst 96:629-32. 2004..Future studies should consider sharing trial results with patients and evaluating the process and its effect on both patients and clinicians...
Direct-to-consumer advertising in oncologyGregory A Abel
Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114-2617, USA
Oncologist 11:217-26. 2006..Although sparse, the medical literature on this increasingly prevalent type of medical communication is also reviewed...
Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantationStephanie J Lee
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 104:2194-200. 2004....
Ethics consultation in children's hospitals: results from a survey of pediatric clinical ethicistsJennifer C Kesselheim
Department of Pediatric Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Pediatrics 125:742-6. 2010..We conducted a national survey of ethicists at freestanding children's hospitals to explore the structures and processes of their ethics-consultation services and committees and to characterize their training and professional activities...
Relationships between authorship contributions and authors' industry financial ties among oncology clinical trialsSusannah L Rose
Department of Health Care Policy, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 28:1316-21. 2010..CONCLUSION Authors who perform key roles in the conception and design, analysis, and interpretation, or reporting of oncology clinical trials are more likely than authors who do not perform such roles to have financial ties to industry...
Parents' views of cancer-directed therapy for children with no realistic chance for cureJennifer W Mack
Center for Outcomes and Policy Research and Department of Pediatric Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 26:4759-64. 2008..We assessed parents' experiences with treatment for their children with cancer and no realistic chance of cure...
Inflammatory bowel disease associated with immune thrombocytopenic purpura in childrenL M Higuchi
Combined Program in Pediatric Gastroenterology and Nutrition, Children s Hospital, 300 Longwood Avenue, Boston, MA 02115, USA
J Pediatr Gastroenterol Nutr 33:582-7. 2001..To date, only five children with both diseases have been described. The aim of the study was to describe the characteristics of children with IBD and ITP...
Compact versus contract--industry sponsors' obligations to their research subjectsMichelle M Mello
Harvard School of Public Health, Boston, USA
N Engl J Med 356:2737-43. 2007
Discontinuing bevacizumab in patients with glioblastoma: an ethical analysisJennifer C Kesselheim
Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
Oncologist 16:1435-9. 2011..With the increasing availability of new, modestly toxic, expensive drugs for patients with advanced cancer, questions of when to stop these drugs will become increasingly relevant...
The challenge of research on ethics educationJennifer C Kesselheim
Dana-Farber Cancer Institute, Department of Pediatric Oncology, Boston, MA 02115, USA
Am J Bioeth 8:12-3; author reply W1-2. 2008
Rethink "affirmative agreement," but abandon "assent"Steven Joffe
Dana-Farber Cancer Institute and Children's Hospital, Boston
Am J Bioeth 3:9-11. 2003
Ethical issues in cancer genetics: I 1) whose information is it?Katherine A Schneider
Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, SM331, Boston, MA 02115, USA
J Genet Couns 15:491-503. 2006..e. duty to warn). We also provide a summary of consensus points and additional discussion questions for each case...
Informed consent for medical treatment and research: a reviewMarcela G del Carmen
Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
Oncologist 10:636-41. 2005..S., highlight how consent to research differs from consent to treatment, and explore the difficulties that arise in research involving cancer patients and certain vulnerable populations...
Quality of informed consent in cancer clinical trials: a cross-sectional surveyS Joffe
Department of Paediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Lancet 358:1772-7. 2001..Efforts to educate providers and participants about the underlying goals of clinical trials are needed...
Individual physician practice variation in hematopoietic cell transplantationStephanie J Lee
Division of Clinical Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D5 290, Seattle, WA 98109, USA
J Clin Oncol 26:2162-70. 2008..Previous studies have evaluated practice variation in hematopoietic cell transplantation (HCT) among transplant centers and countries. There are no studies investigating individual physician practice variation in HCT...
Dana-Farber Cancer Institute ethics rounds: life-threatening illness and the desire to adoptMargaret O Little
Kennedy Institute of Ethics, Georgetown University, Washington, DC, USA
Kennedy Inst Ethics J 15:385-93. 2005....
Children are not small adults: documentation of assent for research involving childrenDavid Ungar
Division of Pediatric Hematology Oncology, Penn State Children s Hospital, Hershey, PA 17033, USA
J Pediatr 149:S31-3. 2006..Current practice for documenting assent is derived largely from documentation of informed consent for adults as there is little guidance in federal regulations. We propose a new approach to documenting assent...
Altruistic discourse and therapeutic misconception in research informed consentSteven Joffe
Dana-Farber Cancer Institute and Children's Hospital
Am J Bioeth 6:53-4. 2006
Patients' views on financial conflicts of interest in cancer research trialsLindsay A Hampson
Department of Clinical Bioethics, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
N Engl J Med 355:2330-7. 2006..A substantial minority wanted to be informed about the oversight system to protect against financial conflicts of interest and about researchers' financial interests. Copyright 2006 Massachusetts Medical Society...
Informed consent from the doctor?Steven Joffe
Harvard Medical School, USA
Hastings Cent Rep 34:12; discussion 12-3. 2004
Clinical trials and medical care: defining the therapeutic misconceptionGail E Henderson
University of North Carolina at ChapelHill, Chapel Hill, North Carolina, United Statesof America
PLoS Med 4:e324. 2007
Evaluating the therapeutic misconceptionFranklin G Miller
Department of Clinical Bioethics, National Institutes of Health, Bethesda, MD, USA
Kennedy Inst Ethics J 16:353-66. 2006..After clarifying the ethical significance of the therapeutic misconception with respect to the decision making of patients, we offer policy recommendations for obtaining informed consent to participation in clinical trials...
Bench to bedside: mapping the moral terrain of clinical researchSteven Joffe
Hastings Cent Rep 38:30-42. 2008..We need an entirely new conception of clinical research ethics - one that looks to science instead of the doctor-patient relationship...
Frequency, type, and monetary value of financial conflicts of interest in cancer clinical researchLindsay A Hampson
Department of Bioethics, The Clinical Center, National Institutes of Health, Bethesda, MD 20892 1156, USA
J Clin Oncol 25:3609-14. 2007..Using data from American Society of Clinical Oncology (ASCO) Annual Meetings, we determined the frequency, type, and monetary value of researchers' financial interests...
Incidental findings in human subjects research: what do investigators owe research participants?Franklin G Miller
Department of Bioethics, National Institutes of Health, USA
J Law Med Ethics 36:271-9, 211. 2008....
ASCO core valuesRebecca D Pentz
Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
J Clin Oncol 24:5780-2. 2006
Research Grants
- Returning Individual Genetic Results to Participants in Cohort StudiesSteven Joffe; Fiscal Year: 2009..These data will help shape practice and policy regarding the return of individual results from genomic research. ..
- Ethical Challenges in Cancer Clinical ResearchSteven Joffe; Fiscal Year: 2006..Joffe's development as a local and national resource in research ethics for the oncology community. ..
- Compliance with adverse event reporting requirements in cancer clinical trialsSteven Joffe; Fiscal Year: 2007..Finally, public trust in and support for the research enterprise itself requires rigorous attention to the identification and management of adverse events. ..
- Returning Individual Genetic Results to Participants in Cohort StudiesSteven Joffe; Fiscal Year: 2010..These data will help shape practice and policy regarding the return of individual results from genomic research. ..
- Accountability and the Role of the Principal Investigator in Multicenter TrialsSteven Joffe; Fiscal Year: 2010..The findings of this proposal will either reaffirm trust in these trials, or will stimulate the development of enhanced systems of accountability for clinical research ..
